JADE: phase 3 study of sequential dostarlimab post chemoradiotherapy in patients with locally advanced unresected HNSCC [0.03%]
JADE III期研究：术前化疗放疗后序贯达洛西利玛b单药治疗局部晚期不可切除性HNSCC患者
Lillian L Siu,Barbara Burtness,Kevin Harrington et al.
Lillian L Siu et al.
Introduction: Head and neck squamous cell carcinoma (HNSCC) accounts for approximately 5% of cancer cases worldwide, with more than half of patients presenting with locally advanced (LA) disease. Treatment of LA HNSCC is ...
Molecular preselection of pediatric patients with solid tumors treated with tyrosine kinase inhibitors [0.03%]
酪氨酸激酶抑制剂治疗实体瘤儿童患者分子预选研究
Peter Sisovsky,Nikola Gejgusova,Tomas Fazekas et al.
Peter Sisovsky et al.
Aim: To review how molecular preselection and combination treatment affects overall response rate (ORR) in pediatric non-central nervous system (CNS) solid tumors treated with tyrosine kinase inhibitors (TKIs). ...
Prognostic value of the glucose-to-lymphocyte ratio in surgically treated endometrial cancer: a retrospective cohort study [0.03%]
糖脂比在手术治疗子宫内膜癌患者预后价值的队列研究
Furkan Ceylan,Serhat Sekmek,Ateş Kutay Tenekeci et al.
Furkan Ceylan et al.
Background: The glucose-to-lymphocyte ratio (GLR) has recently gained attention as a composite biomarker reflecting systemic inflammation and metabolic dysregulation. While its prognostic value has been reported in variou...
Plain language summary of the management of certain side effects of teclistamab in people with multiple myeloma [0.03%]
关于teclistamab治疗多发性骨髓瘤时某些不良反应管理的通俗概述
Thomas G Martin,Niels W C J van de Donk,Paula Rodríguez-Otero et al.
Thomas G Martin et al.
Avelumab real-world use in advanced Merkel cell carcinoma: a systematic review and non-comparative meta-analysis [0.03%]
阿维鲁单抗在晚期默克尔细胞癌中的真实世界应用：系统性回顾和非比较性meta分析
Andreas Freitag,Zhiyi Lan,Hoora Moradian et al.
Andreas Freitag et al.
Aim: Programmed death (ligand) 1 inhibitors (e.g., avelumab, pembrolizumab, and retifanlimab) are first-line treatment options for patients with locally advanced or metastatic Merkel cell carcinoma (MCC). In the absence o...
Machine learning-based prediction of central lymph node metastasis in unifocal papillary thyroid microcarcinoma [0.03%]
基于机器学习的单发病灶乳头状甲状腺微小癌中央区淋巴结转移预测
Xi Dai,Xiaoyu Zhou,Yating Ruan et al.
Xi Dai et al.
Objective: This study aims to develop a machine learning (ML) model to predict the risk of central lymph node metastasis (CLNM) in patients with papillary thyroid microcarcinoma (PTMC) using a combination of clinical and ...
Impact of antiemetic prophylaxis on reducing trastuzumab deruxtecan dose modifications in HER2+/HER2-low breast cancer [0.03%]
止吐预防对减少HER2+/HER2低乳腺癌曲妥珠单抗德鲁克斯剂量调整的影响
Junghoon Shin,Ji-Yeon Kim,Hee Kyung Ahn et al.
Junghoon Shin et al.
Background: Avoiding unnecessary dose reductions is important for patients with advanced breast cancer (ABC) receiving trastuzumab deruxtecan (T-DXd). Nausea and vomiting, the most common adverse events of T-DXd, frequent...
Characteristics and outcomes of patients with HCC treated with atezolizumab/bevacizumab, stratified by second line therapy [0.03%]
阿特朱单抗/贝伐珠单抗治疗肝细胞癌患者的特征及疗效：二线疗法亚组分析
Amit G Singal,Kirhan Özgürdal,Zdravko Vassilev et al.
Amit G Singal et al.
Background: Atezolizumab plus bevacizumab (atezo+bev) is a standard-of-care 1L treatment for unresectable hepatocellular carcinoma (uHCC). Understanding its adoption and use, clinical outcomes, and subsequent therapies ar...
Lorlatinib atypical safety profile in ALK-positive aNSCLC: tips for management from an Italian expert panel [0.03%]
lorlatinib治疗ALK阳性晚期非小细胞肺癌(atypical)的安全性特征及意大利专家组管理建议
Andrea Ardizzoni,Diego Cortinovis,Bruno Gori et al.
Andrea Ardizzoni et al.
Lorlatinib is a third-generation tyrosine kinase inhibitor approved for first- and second-line treatment of ALK-positive advanced non-small cell lung cancer. The CROWN study demonstrated that first-line lorlatinib significantly improves pro...
Matching-adjusted indirect treatment comparison of A+AVD vs PET-guided ABVD in newly diagnosed advanced Hodgkin lymphoma [0.03%]
一种匹配调整的间接治疗比较：A+AVD与PET指导下的ABVD在新诊断的晚期霍奇金淋巴瘤中的疗效对比研究
Fjoralba Kristo,Alexa Molinari,Zhiyi Lan et al.
Fjoralba Kristo et al.
Aims: The study team investigated the relative efficacy of brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) versus positron emission tomography (PET)-guided doxorubicin, bleomycin, vinblastine, and d...